• MacroGenics reported positive interim Phase 1 results for MGC026 in advanced solid tumors, presented today at the ESMO 2026 Congress.
• Treatment produced durable tumor responses across multiple cancer types, including activity in heavily pretreated patients with head and neck cancer.
• Safety was manageable in the head and neck cancer group, with no treatment-related discontinuations.
• A front-line study combining MGC026 with pembrolizumab in PD-L1-positive recurrent or metastatic head and neck cancer is planned for early 2027.
• Enrollment continues in the ongoing Phase 1 expansion cohort, with updated results expected in mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230915PRIMZONEFULLFEED9851467) on October 23, 2026, and is solely responsible for the information contained therein.